Duokopt

Quick links to important sections

Duokopt

Treatment option: Glaucoma

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Duokopt

Property Description
Active ingredient Dorzolamide, Timolol
Form Ophthalmic solution (Eye drops)
Pharmacological class Fixed Combination, Ophthalmic Glaucoma Agent
Common use Elevated Intraocular Pressure (IOP)
Origin Synthetic

What Type of Ophthalmic Medication is Duokopt?

Duokopt is classified as a fixed-dose combination product, specifically an Ophthalmic Glaucoma Agent, delivered as a sterile ophthalmic solution for topical ocular use. This synthetic medication is a unified pharmaceutical preparation designed to manage conditions characterized by elevated intraocular pressure (IOP). The drug's design as a fixed-dose combination signifies that it contains two distinct active components in a single dosage form, simplifying administration and ensuring the simultaneous delivery of both therapeutic actions, a strategy for optimizing patient adherence.

What Active Ingredients are in Duokopt's Composition?

The two primary active ingredients in Duokopt are dorzolamide and timolol, delivered as their corresponding salts, dorzolamide hydrochloride and timolol maleate, within an aqueous solution base. Dorzolamide belongs to the pharmacological group of topical carbonic anhydrase inhibitors, while Timolol is a non-selective beta-adrenergic antagonist or topical beta-blocker. This specific combination is an option for patients requiring more than one type of pressure-lowering medicine. The fixed-dose pairing of a carbonic anhydrase inhibitor with a beta-blocker represents a standard pharmacological strategy in modern glaucoma management.

What is the General Benefit of the Fixed-Dose Combination?

The general benefit is achieving a reduction of elevated intraocular pressure, which is the critical necessity in managing conditions such as ocular hypertension and open-angle glaucoma. The dual action mechanism of Duokopt, combining the efforts of the two pharmacological classes, ensures control over fluid dynamics within the eye. This combined approach, relying on the additive effect, is typically prescribed to adult patients who have not achieved adequate target pressure control with a single beta-adrenergic receptor blocking agent alone. Duokopt's formulation offers a specific solution for those needing the combined efficacy of two agents without the difficulty of managing multiple drop schedules.

What side effects are possible with Duokopt?

Possible side effects and safety information

The official safety profile for the dorzolamide/timolol ophthalmic solution is categorized based on the incidence and nature of reported adverse reactions. Because this topical medicine is subject to systemic absorption, adverse effects documented for oral beta-blockers and sulfonamide-derived medications may occur, affecting non-ocular systems.

Frequency-Classified Adverse Reactions

Adverse reactions are formally grouped by regulatory authorities:

  • Very Common (Affecting 1 in 10 people or more): Ocular burning and stinging, taste perversion (dysgeusia).
  • Common (Affecting 1 in 100 to less than 1 in 10 people): Headache, blurred vision, conjunctival hyperemia, superficial punctate keratitis, eyelid irritation, and fatigue.

Systemic Safety Considerations

The adverse reactions are associated with several System-Organ Classes (SOCs), including Eye Disorders, Nervous System Disorders, Gastrointestinal Disorders, and Cardiovascular Disorders. Local ocular adverse effects, such as conjunctivitis and lid reactions, have been specifically reported with chronic administration.

Serious Adverse Reactions and Restrictions

Regulatory documentation highlights serious adverse reactions, including the potential for severe respiratory reactions (such as bronchospasm) and cardiac failure, which are associated with the systemic absorption of the beta-blocker component. For safety, the medicine is contraindicated in individuals with pre-existing conditions such as bronchial asthma, severe chronic obstructive pulmonary disease, certain heart rhythm abnormalities, and severe renal impairment.

Population-Specific Safety Notes

Due to the beta-blocker component, the medication may mask certain signs of hyperthyroidism or acute hypoglycemia in diabetic patients. The safety and effectiveness of the solution have not been established in pediatric patients.

Overdose and Emergency Response

The official regulatory profile for Duokopt overdose is defined by the systemic effects resulting from the combined absorption of its two active components, dorzolamide and timolol.

Documented signs and symptoms of overdose primarily involve the Central Nervous System and Cardiovascular System. These manifestations may include confusion, seizures, trembling, dizziness, and headache. Systemic effects can also involve slow heartbeat (bradycardia), irregular heartbeat, shortness of breath, or difficulty breathing.

Overdose scenarios may result in severe or life-threatening outcomes. These risks are linked to the drug's components, including cardiac failure or death due to bronchospasm from the timolol component, and the development of metabolic acidosis or severe electrolyte imbalance from the dorzolamide component. Patients with severe renal impairment are noted to be at an increased risk of accumulation, which may exacerbate overdose symptoms.

In any suspected overdose, official guidance mandates that you seek immediate medical attention. If the individual has collapsed, is seizing, has trouble breathing, or cannot be awakened, contact emergency services immediately. There is no specific antidote known, and management is restricted to symptomatic and supportive treatment, including the mandatory monitoring of serum electrolyte levels and blood pH.

Therapeutic Uses of Duokopt

Duokopt: Therapeutic Uses

Duokopt is a prescription medication utilized in ophthalmology for the management of elevated pressure within the eye. This elevation, known as intraocular pressure (IOP), is a significant factor associated with conditions that can affect vision.

The primary therapeutic applications for Duokopt include addressing two key ocular conditions where IOP is raised: open-angle glaucoma and ocular hypertension. In these contexts, the medication is employed to assist in the sustained lowering of the pressure within the eye. Consistent management of IOP is considered a core objective in the care of these conditions, helping to support long-term ocular health and visual function.

Duokopt may be prescribed when an eye drop treatment containing a single beta-blocker component has not been sufficient to achieve the appropriate level of pressure control. It is an established therapeutic option for individuals requiring adjunctive treatment to maintain target pressure levels.


Quick Facts

  • Primary Use: Supports the reduction of elevated intraocular pressure (IOP).
  • Conditions Managed: Used to address open-angle glaucoma.
  • Secondary Use: Indicated for the management of ocular hypertension.

Regulatory References

  1. NIH MedlinePlus guidance on Dorzolamide and Timolol Ophthalmic

Eligibility and Restrictions for Use

Eligibility Profile: Populations for Duokopt

Official regulatory documents define strict criteria for patients who must not use this medicine due to the systemic effects of its components (a beta-blocker and a carbonic anhydrase inhibitor). The medicine is strictly contraindicated for patients with:

  • Respiratory Disease: History of bronchial asthma or severe chronic obstructive pulmonary disease (COPD).
  • Cardiac Conditions: Sinus bradycardia, second or third-degree atrioventricular block, overt cardiac failure, or cardiogenic shock.
  • Hypersensitivity: Known allergy to either active substance or any excipient, including an allergy to sulfonamides.

Restricted or Not Recommended Use

The medicine is not recommended for use in patients with severe renal impairment (creatinine clearance < 30 mL/min) because the dorzolamide component and its metabolite are primarily excreted by the kidneys. Use is also not recommended during pregnancy or breastfeeding.

Age and Pediatric Status

Safety and effectiveness have not been established in children and adolescents (generally under 18 years of age); therefore, use is not authorized for this population.

What should I know about interactions with other medicines?

Duokopt Interactions with other medicines and products

The interaction profile for Duokopt, a combination ophthalmic solution containing dorzolamide and timolol, is primarily structured around the potential for additive systemic effects from its components.


Formal Restrictions and Prohibitions

Co-administration with Oral Carbonic Anhydrase Inhibitors is not recommended due to the risk of compounded systemic effects, including acid-base and electrolyte disturbances. The use of other Topical Beta-Adrenergic Blocking Agents is also restricted, as it offers no additional therapeutic benefit and increases the risk of potentiated systemic beta-blockade.


Pharmacodynamic and Exposure Potentiation

Because the timolol component is systemically absorbed, interaction potential exists with agents that affect the heart and blood pressure. Concomitant use with Systemic Beta-Adrenergic Blocking Agents may potentiate systemic beta-blockade. Co-administration with Calcium Antagonists or Catecholamine-Depleting Drugs (e.g., reserpine) may cause additive effects, resulting in hypotension or marked bradycardia. Furthermore, CYP2D6 inhibitors such as quinidine or fluoxetine can reduce the clearance of the timolol component, leading to potentiated systemic effects.


Administration Rules and Population Notes

To prevent drug washout, other topical ophthalmic drugs must be administered at least five minutes apart from Duokopt. Due to the renal excretion of dorzolamide, the medication is not recommended for patients with severe renal impairment (Creatinine Clearance <30 mL/min).

Mechanism of Action

Enzyme Inhibition and Receptor Blockade

Duokopt's mechanism of action relies on two distinct and complementary pharmacodynamic actions that converge to modulate the production of aqueous humor within the eye. The dorzolamide component involves the localized competitive inhibition of the enzyme Carbonic Anhydrase Isoenzyme II (CA-II), which is concentrated in the ciliary body. Blocking CA-II disrupts the active transport of bicarbonate ions and water, thereby decreasing the rate of fluid secretion.

Simultaneously, the timolol component acts as a non-selective antagonist of beta1- and beta2-adrenergic receptors (beta-AR). This antagonism prevents the activation of Adenylyl Cyclase, reducing the intracellular level of cyclic AMP (cAMP). This signal modulation causes a separate functional reduction in aqueous humor secretion.

These dual mechanisms—enzyme inhibition and receptor blockade—target different molecular sites but yield an additive effect, resulting in a systemic physiological reduction of intraocular pressure (IOP).

Dosage and Administration Information

How Duokopt Is Used: Administration Guidelines

Duokopt (dorzolamide/timolol ophthalmic solution) is used according to specific procedural and quantitative requirements.


Standard Dosing and Frequency

Administration Detail Standard Requirement
Route of Administration Topical Ocular (into the affected eye(s))
Standard Adult Dose One drop
Dosing Frequency Two times daily (typically morning and evening)
Strength Dorzolamide 20 mg/mL and Timolol 5 mg/mL
Timing in Relation to Meals Independent of food intake

Procedural and Population-Specific Instructions

Instructions for the proper application of the solution include:

  • Spacing of Drops: If using other topical ophthalmic drugs, they must be administered at least five or ten minutes apart from Duokopt.
  • Contamination Avoidance: Avoid allowing the tip of the dispensing container to touch the eye or surrounding structures to prevent contamination.
  • Systemic Absorption Reduction: After administration, it is recommended to apply nasolacrimal occlusion (pressing on the inner corner of the eye) or gently close the eyelids for 2 minutes.
  • Contact Lenses: Soft contact lenses must be removed before application and may be reinserted 15 minutes afterwards, as the preservative (if present) can be absorbed by the lenses.
  • Missed Dose: If a dose is missed, it is generally advised to skip the missed dose and continue with the next scheduled dose; do not use a double dose to make up for a missed one.
  • Special Population Use: The medicine is not recommended for use in patients with severe renal impairment (CrCl < 30 ml/min), and safety and efficacy have not been established in the pediatric population (under 18 years of age).

Recent Clinical Evidence

Research Evidence / Overview of Studies for Duokopt


Evidence for Use in Open-Angle Glaucoma and Ocular Hypertension

The research into the dorzolamide/timolol fixed combination, which is applied in research contexts involving fluctuating or unstable symptoms for conditions like primary open-angle glaucoma (POAG) and ocular hypertension (OH), is primarily based on Randomized Controlled Trials (RCTs). These RCTs compare the combination eye drop to other treatment approaches to study the measurements of eye pressure. The majority of studies have explored its use in adult patients who were included in research comparing the combination to a topical beta-blocker medicine. This research describes the patterns observed when a dual-action medication is evaluated in a comparative setting.

The core research focused on outcomes related to systemic or functional imbalance within the eye, primarily the change in pressure inside the eye, known as Intraocular Pressure (IOP). Studies monitored the change in IOP, often recording measurements multiple times a day over defined time intervals. The findings describe patterns observed in the studies when comparing the fixed combination to both its individual components and other single-component medicines.


Research on Long-Term Outcomes and Follow-Up Duration

While the core studies research examined short-to-intermediate changes, often over periods of three to six months, limited long-term data are available. These shorter, controlled trials were crucial for regulatory evaluation, but they provide limited information for long-term outcomes beyond the initial assessment period. Extended observational studies look at patterns of IOP measurements over longer durations, such as a year or more, but the evidence contributing to understanding symptom patterns over many years is less defined than the data on the immediate and short-term IOP measurements.


Gaps and Uncertainties in the Research Evidence

The scientific literature highlights several areas where more information is needed. Long-term effects are not fully established regarding how the fixed combination affects the physical progression of glaucoma—such as changes to the optic nerve or visual field—over many years of continuous use. Most findings describe group patterns, not personal outcomes, and the results apply only to the populations studied. Furthermore, data for certain groups remain insufficient, meaning the certainty remains low when trying to apply the findings to rare forms of glaucoma or complex concurrent conditions.

Key Studies & References

  1. Dorzolamide/Timolol Mylan 20mg/ml + 5mg/ml Eye drops, Solution - Summary of Product Characteristics (SMPC)

Frequently Asked Questions (FAQ)

Common questions about Duokopt (FAQ)


Q: What does 'intraocular pressure' mean in simple terms?

High intraocular pressure (IOP) refers to elevated fluid pressure inside the eye. Official information indicates that medications like Duokopt are used to modulate this pressure, consistent with treatment goals aimed at reducing the risk of damage to the optic nerve.

Q: What does the term 'contraindication' mean for Duokopt?

A contraindication is a circumstance or condition described in regulatory documents where the drug should not be used. This is based on an assessment where the potential risks of using the medication are considered to be greater than any potential benefit.

Q: How long does the pressure-lowering effect of Duokopt last?

Official information regarding one of the components indicates that the pressure-lowering effect can last for as long as 24 hours. The drug is typically administered at specific intervals, which aligns with the duration of its pressure-lowering effect.

Q: What should I avoid doing while using Duokopt?

Regulatory documents advise caution when driving or operating potentially dangerous machinery because the medication may cause temporary blurred vision or dizziness. Avoiding contact between the dispensing container tip and the eye or surrounding structures is also advised in procedural documents.

Q: What should I do if my eye feels dry while using Duokopt?

Dryness of the eyes is listed in product information as a potential side effect. If any side effect, including dryness, is persistent or becomes bothersome, consulting a healthcare professional is generally described in patient information.

Q: Is it common to feel a slight stinging when using Duokopt?

Ocular burning, stinging, or discomfort immediately following administration is described in official product information as one of the most frequently reported adverse reactions in clinical studies. This sensation is noted to occur in a portion of patients.

Q: Is it normal to have blurred vision right after applying Duokopt?

Yes, blurred vision is listed as a common adverse reaction. Product information notes that vision may become temporarily blurred, and caution is advised until vision clears before resuming activities like driving or operating machinery.

Q: Does Duokopt have a bitter taste if it drains into the throat?

A bitter taste following administration is reported in official documents as a common experience for some patients in clinical studies. This sensation is related to the solution draining through the nasolacrimal duct.

Q: What is Duokopt used for besides its main purpose?

The official product indications are for the treatment of elevated intraocular pressure (IOP) in patients who have been diagnosed with either open-angle glaucoma or ocular hypertension. Official regulatory documents only cover approved uses.

Q: Is Duokopt the same as combining two separate eye drops?

No, this is a fixed-combination product. It contains two different active ingredients in a single solution, which is administered as one drop. It is generally used when a patient requires the therapeutic effects of both specific agents.

Q: Is Duokopt used for long-term treatment?

Official patient information indicates that the medication is intended for regular, ongoing use. For chronic conditions, official patient information indicates that continued use is generally necessary.

Q: How quickly does Duokopt start working after I begin using it?

Official data regarding one of the components indicates a fast onset of action, with effects on eye pressure typically observed within 20 minutes of administration. Consistent use is advised to maintain the overall intended pressure-lowering effect.

Q: Do the side effects of Duokopt go away after a while?

Official information notes that some side effects may occur that usually do not need specific medical attention and may resolve as the body adjusts to the medicine. Users are advised to contact a healthcare professional if side effects continue or are bothersome.

Q: Can Duokopt cause headaches or dizziness?

Headache and dizziness are both listed among the adverse reactions reported in official product information. These systemic effects may occur because the medication is absorbed by the body after administration.

Q: Is it possible for Duokopt to affect my sleep?

Regulatory information indicates that neuropsychiatric adverse events have been reported for the timolol component of the medication. This suggests a possibility of central nervous system-related effects.

Q: Are there any long-term side effects associated with Duokopt use?

Official documents list adverse effects observed with chronic administration of the components. Furthermore, official information acknowledges rare, severe systemic reactions that have been reported with related medicines, which are noted as potential risks.

Q: Does Duokopt contain preservatives?

The product is available in two main formats: a multi-dose formulation that typically contains a preservative (such as benzalkonium chloride), and a preservative-free formulation, which is usually offered in single-dose containers.

Q: Are there food or drink restrictions while using Duokopt?

Official product information, such as monographs and patient safety sheets, primarily focuses on drug-drug interactions. These sources generally do not list specific restrictions regarding food or drink intake for this ophthalmic solution.

Q: Is Duokopt safe to use during pregnancy?

Official warnings state that the use of the drug during pregnancy is considered only if the potential benefit is assessed to justify the potential risk to the fetus. Monitoring of the neonate is advised if the medicine is administered until delivery.

Q: Why would a doctor switch me from another eye drop to Duokopt?

The product is officially indicated for use when a combination of medicines is appropriate or for patients who have not responded sufficiently to a single-agent ophthalmic beta-blocker. The combination is often indicated when a patient needs the dual mechanism of action, which may contribute to achieving the therapeutic pressure goal.

Q: Is Duokopt a treatment for glaucoma or for ocular hypertension?

Official indications for the product include the treatment of elevated intraocular pressure in patients with both open-angle glaucoma and ocular hypertension. These are the two primary conditions for which the drug is authorized.

Q: Does Duokopt come in a generic version?

Official government databases, such as DailyMed, list non-branded versions of the dorzolamide and timolol ophthalmic solution. This indicates that generic or non-branded options are available.

Q: Can Duokopt cause an allergic reaction?

Official documents report signs of ocular allergic reaction in clinical studies. Due to the sulfonamide component, there is also a rare potential for severe systemic allergic reactions, which are noted in official warnings.

Q: Can I use Duokopt if I have other eye diseases?

Product information notes that use is advised with caution for patients with a current eye infection, recent eye surgery, or a history of cornea problems. Specific warnings are in place to guide proper use under these circumstances.

Q: Does Duokopt affect driving or operating machinery?

Regulatory documents advise due caution when driving or operating machinery, as the medication may cause temporary blurred vision or dizziness. Users should wait until these effects have passed before performing such activities.

Q: Is the medication still working if I don't feel anything after putting it in?

Official patient information notes that most people with the condition this drug treats do not feel sick or have noticeable symptoms from the pressure. Official information suggests continuing regular use as intended.

Q: What is the recommended age range for Duokopt use?

Official documents state that safety and efficacy have not been established in children younger than 2 years of age. For children 2 years of age and older, the appropriate use and quantity must be determined by a healthcare professional.

How should Duokopt be stored and disposed of?

How to Store and Dispose of Duokopt?

The proper storage and disposal of Duokopt ophthalmic solution are defined by regulatory labeling to maintain the product's quality and safety.

Official Storage Requirements

Duokopt must be stored at room temperature, generally between 15 C and 25 C (up to 30 C for some preserved versions). The medication must not be refrigerated or frozen. To protect the active ingredients from degradation, always keep the container tightly closed and store the bottle or single-use pouches in the original outer carton away from light.

Stability and Disposal Rules

For the multi-dose bottle, any remaining solution must be discarded 28 days after first opening. Single-dose containers must be discarded immediately following a single use. All Duokopt products must be stored out of the sight and reach of children. Unused or expired medicine should not be disposed of in household waste or flushed down the toilet; ask a healthcare professional for guidance on disposal programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Duokopt found in:

A-Z Index: